Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis

Table 4 Numbers of the questions from patients regarding DAAs treatment

Type of questions	Number (%)
Adverse drug events	577 (53.8%)
Drug interaction ^a	205 (19.1%)
Management in the event of a missed dose of DAAs	57 ( 5.3%)
Others	233 (21.8%)
TOTAL	1,072 (100%)

DAAs Direct-acting antivirals
^a These included questions according to drug-drug (152 cases), drug-supplement (32 cases), and drug-food (21 cases) interactions

ISSN: 2055-0294